Amphilimus Eluting Stent
DeviceSirolimus formulated coronary eluting stent
NCT Number: NCT01543373
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal coverage, determined by Optical Coherence Tomography (OCT), as percentage of cross-sections with RUTTS (Ratio of Uncovered to Total Stent Struts Per Cross Section) score ≤ 0.3.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Azienda Ospedaliero - Universitaria S.Anna, Ferrara, FE, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sirolimus formulated coronary eluting stent
Bare metal coronary stent
Time frame: within 3 months from index procedure
1 month for the BMS arm; 3 months for the DES arm
Time frame: Immediately post index procedure, 1 month (BMS arm) / 3 months (DES arm)
Time frame: 1 month (BMS arm) / 3 months (DES arm)
Time frame: 1 month (BMS arm) / 3 months (DES arm)
Time frame: immediately pre and post index procedure, 1 month (BMS arm) / 3 months (DES arm)
reference vessel diameter; minimal lumen diameter; % diameter stenosis; binary restenosis; late lumen loss
Time frame: At 1, 3 and 12 months
Time frame: during index procedure, immediately after index procedure, 1 month, 3 months, 12 months
CID - Carbostent & Implantable Devices
Industry
Randomized Comparison Between a DES and a BMS to Assess Neointimal Coverage by OCT Evaluation
Acronym: DEMONSTRATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01539603
Angina Pectoris, Angina, Stable
Seongnam, South Korea
View Trial DetailsNCT04861519
Angina Pectoris, Angina, Stable
Hadera, Central District, Israel
View Trial DetailsNCT03690713
Angina Pectoris, Angina, Stable
Tokyo, Japan
View Trial DetailsNCT03389503
Angina Pectoris, Angina, Stable
Wŏnju, Gangwon-do, South Korea
View Trial Details